Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

Javle, M.; Yu, J.; Garrett, C.; Pande, A.; Kuvshinoff, B.; Litwin, A.; Phelan III, J.; Gibbs, J.; Iyer, R.
June 2009
British Journal of Cancer;6/16/2009, Vol. 100 Issue 12, p1842
Academic Journal
A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg−1, capecitabine 1300 mg m−2 daily for 2 weeks and gemcitabine 1000 mg m−2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).British Journal of Cancer (2009) 100, 1842–1845; doi:10.1038/sj.bjc.6605099; published online 2 June 2009; www.bjcancer.com


Related Articles

  • Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Ferrari, Vittorio; Valcamonico, Francesca; Amoroso, Vito; Simoncini, Edda; Vassalli, Lucia; Marpicati, Patrizia; Rangoni, Giovanni; Grisanti, Salvatore; Tiberio, Guido A. M.; Nodari, Franco; Strina, Carla; Marini, Giovanni // Cancer Chemotherapy & Pharmacology;Feb2006, Vol. 57 Issue 2, p185 

    Introduction: Single agent gemcitabine (GEM) is the standard treatment of pancreatic adenocarcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. Recent studies in human pancreatic tumor cell lines suggest an involvement of COX-2 in tumor-dependent angiogenesis and provide the...

  • Bevacizumab and central nervous system (CNS) hemorrhage. Letarte, Nathalie; Bressler, Linda; Villano, John // Cancer Chemotherapy & Pharmacology;Jun2013, Vol. 71 Issue 6, p1561 

    Background: Bevacizumab is widely used and may cause life-threatening bleeding. We attempted to identify clinical characteristics associated with central nervous system (CNS) hemorrhage in a broad population. Methods: We performed a retrospective review of the FDA MedWatch database of adverse...

  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Fogelman, David; Jafari, Mehrdad; Varadhachary, Gauri; Xiong, Henry; Bullock, Susie; Ozer, Harold; Lin, E.; Morris, Jeffrey; Cunningham, Patti; Bennett, Bronwyn; Abbruzzese, James; Wolff, Robert // Cancer Chemotherapy & Pharmacology;Dec2011, Vol. 68 Issue 6, p1431 

    Purpose: The gemcitabine and oxaliplatin (GEMOX) has yielded among the longest progression-free survival durations in patients with advanced pancreatic cancer (APC). We postulated that adding bevacizumab would increase the effectiveness of GEMOX. Methods: Eligible patients had stage III or IV...

  • A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. Hirao, Ken; Kawamoto, Hirofumi; Sakakihara, Ichiro; Noma, Yasuhiro; Yamamoto, Naoki; Harada, Ryo; Tsutsumi, Koichiro; Fujii, Masakuni; Kato, Hironari; Kurihara, Naoko; Mizuno, Osamu; Ogawa, Tsuneyoshi; Ishida, Etsuji; Yamamoto, Kazuhide // International Journal of Clinical Oncology;Dec2011, Vol. 16 Issue 6, p637 

    Background: This randomized phase II study compared the efficacy and toxicity between 4-week and 3-week schedules of gemcitabine monotherapy in advanced pancreatic cancer. Methods: Patients with advanced pancreatic cancer were randomly assigned to either a 4-week schedule (gemcitabine at 1000...

  • Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Feliu, J.; Borrega, P.; León, A.; López-Gómez, L.; López, M.; Castro, J.; Belda-Iniesta, C.; Barriuso, J.; Martínez, V.; González-Barón, M. // Cancer Chemotherapy & Pharmacology;Jan2011, Vol. 67 Issue 1, p215 

    Purpose: To evaluate the feasibility, toxicity and efficacy of the combination regimen consisting of gemcitabine-FDR infusion plus erlotinib, in ACP patients. Methods: Forty-two patients with histologically confirmed, locally advanced or metastatic pancreatic cancer were included in this phase...

  • Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Bouganim, N.; Mamo, A.; Wasserman, D. W.; Batist, G.; Metrakos, P.; Chaudhury, P.; Hassanain, M.; Kavan, P. // Current Oncology;Oct2013, Vol. 20 Issue 5, p247 

    Background Before its regulatory approval in Canada, bevacizumab to treat patients with colorectal cancer (CRC) was accessed through the Bevacizumab Expanded Access Trial and a special-access program at the Jewish General Hospital. We retrospectively evaluated patient outcomes in that large...

  • Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Brell, Joanna; Krishnamurthi, Smitha; Rath, Linda; Bokar, Joseph; Savvides, Panayiotis; Gibbons, Joseph; Cooney, Matthew; Meropol, Neal; Ivy, Percy; Dowlati, Afshin // Cancer Chemotherapy & Pharmacology;Oct2012, Vol. 70 Issue 4, p547 

    Purpose: Combining cytotoxic agents with bevacizumab has yielded significant benefits in a number of solid tumors. Combining small-molecule kinase inhibitors of VEGFR with chemotherapy has yet to demonstrate clinical benefit. The dose, schedule and agents used may be critical to the development...

  • Excessive menstruation bleeding as a presentation of dengue hemorrhagic fever. Wiwanitkit, Somsri; Wiwanitkit, Viroj // Archives of Gynecology & Obstetrics;Jun2013, Vol. 287 Issue 6, p1271 

    No abstract available.

  • Evaluating bleeding severity in immune thrombocytopenia (ITP). Neunert, Cindy E. // Annals of Hematology;Jul2010, Vol. 89, p47 

    Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics